Affiliation:
1. Department of Pharmaceutics, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, 391760, India
Abstract
Background:
The Cataract is the leading cause of visual impairment and preventable
blindness worldwide. Cataract removal surgery involves various post-operative complications like
pain and inflammation.
Objectives:
The objective of this study is to screen the polymer concentration as well as optimize the
formulation components to develop the pluronic micelles with nanosized characterization and for enhanced
corneal permeation study.
Methodology:
For optimization, Central Composite design was employed to study the effect of independent
variables, concentration of Pluronic F 127 (X1) and the concentration of Hyaluronic acid (X2)
on chosen responses (Y 1 ) Micelle size, (Y 2 ) Entrapment Efficiency, (Y 3 ) Viscosity. The lyophilised
powder was used for physical characterisation.
Results:
The formulation containing 5%w/v Pluronic F127 and 0.2%w/v Hyaluronic acid was the optimised
composition with micelle size and zeta potential 38.74±4.12nm and -17.6±0.1 mV respectively.
In-vitro drug release was found to be 91.72±1.2 percentage in 8 hours. Surface morphology revealed
micelles were spherical in shape. Ocular irritancy study showed that formulation was safe and
non-irritant. In vitro corneal permeation studies through excised rabbit cornea indicated 1.5 fold increase
in ocular availability without corneal damage compared to an aqueous suspension containing
the same amount of drug in nanomicelles.
Conclusions:
In a nutshell, Pluronic Nanomicelles would be a platform for the delivery of Bromfenac
Sodium.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biomedical Engineering
Reference25 articles.
1. Rajpal R.K.; Ross B.; Rajpal S.D.; Hoang K.; Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: Safety, efficacy, and patient adherence. Patient Prefer Adherence 2014,8,925-931
2. Cho H.; Wolf K.J.; Wolf E.J.; Management of ocular inflammation and pain following cataract surgery: Focus on bromfenac ophthalmic solution. Clin Ophthalmol 2009,3,199-210
3. Ghlichloo I, Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Available from: (Accessed on May 12, 2021).
4. Yanni J.M.; Graff G.; Hellberg M.R.; Topically administrable compositions
containing 3-benzoylphenylacetic acid derivatives for treatment
of ophthalmic inflammatory disorders. Fort Worth, TX: Alcon
Laboratories, Inc U.S. Patent 5475034, 1995.
5. Waterbury L.D.; Silliman D.; Jolas T.; Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 2006,22(6),1133-1140
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献